Literature DB >> 26509849

Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary.

Jennifer J Mueller1, Marie Holzapfel, Chan H Han, Kevin Santos, Camille Gunderson, Kathleen Moore, Britt Erickson, Charles A Leath, Elena Diaz, Christine Walsh, Stephanie L Wethington, Sheila Z Dejbakhsh, Richard R Barakat, Ginger J Gardner, David M Hyman, Robert A Soslow, Mario M Leitao.   

Abstract

OBJECTIVE: The purpose of this study was to assess the rate of lymph node (LN) metastasis in comprehensively staged ovarian clear cell carcinoma (OCCC) clinically confined to the ovary and determine factors associated with LN metastasis.
METHODS: We identified all cases of OCCC treated at 4 institutions from January 1994 through December 2011. We included cases with disease grossly confined to the ovary that had surgical staging performed, including at least 10 LNs sampled. Clinical and pathologic data were abstracted from electronic medical records, and a deidentified data set was compiled and processed at a single institution. Factors potentially associated with LN metastasis were tested. Appropriate statistical tests were performed.
RESULTS: We identified 145 eligible cases that met the criteria for this analysis. Median age was 52.9 years (range, 30-81 years), and median total LN count was 19 (range, 10-74). Seven (4.8%) of 145 comprehensively staged cases had LN metastasis; 6 of these cases (4.1%) were isolated metastasis. Cytologic washings, peritoneal, omental, and fallopian tube involvement were not associated with nodal metastasis. Cases with ovarian surface involvement and positive cytology had a 37.5% incidence of LN positivity, which was statistically meaningful when compared with all other cases (P = 0.003).
CONCLUSIONS: Women who underwent comprehensive staging for clinical stage I OCCC had an LN metastasis rate of 4.8%. The subgroup of cases with both ovarian surface involvement and positive cytology had the highest incidence of LN metastasis. This may influence clinical decision making on whether to perform lymphadenectomy in patients with incidental OCCC found after salpingo-oophorectomy.

Entities:  

Mesh:

Year:  2016        PMID: 26509849      PMCID: PMC4891809          DOI: 10.1097/IGC.0000000000000559

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  16 in total

1.  The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer.

Authors:  Akiko Abe; Hiroyuki Furumoto; Minoru Irahara; Hiroyasu Ino; Masaharu Kamada; Osamu Naka; Masaru Sasaki; Toshiaki Kagawa; Osamu Okitsu; Norio Kushiki
Journal:  J Obstet Gynaecol Res       Date:  2010-10       Impact factor: 1.730

2.  The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study.

Authors:  Masashi Takano; Toru Sugiyama; Nobuo Yaegashi; Mitsuaki Suzuki; Hiroshi Tsuda; Satoru Sagae; Yasuhiro Udagawa; Kazuo Kuzuya; Junzo Kigawa; Satoshi Takeuchi; Hitoshi Tsuda; Takuya Moriya; Yoshihiro Kikuchi
Journal:  Int J Gynecol Cancer       Date:  2009-11       Impact factor: 3.437

3.  Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging.

Authors:  Cecelia A Powless; Giovanni D Aletti; Jamie N Bakkum-Gamez; William A Cliby
Journal:  Gynecol Oncol       Date:  2011-06-01       Impact factor: 5.482

4.  Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease.

Authors:  B A Goff; R Sainz de la Cuesta; H G Muntz; D Fleischhacker; M Ek; L W Rice; N Nikrui; H K Tamimi; J M Cain; B E Greer; A F Fuller
Journal:  Gynecol Oncol       Date:  1996-03       Impact factor: 5.482

5.  Systematic para-aortic and pelvic lymphadenectomy in early stage epithelial ovarian cancer: a prospective study.

Authors:  Antonino Ditto; Fabio Martinelli; Claudio Reato; Shigeky Kusamura; Eugenio Solima; Rosanna Fontanelli; Edward Haeusler; Francesco Raspagliesi
Journal:  Ann Surg Oncol       Date:  2012-06-16       Impact factor: 5.344

6.  Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.

Authors:  Jeffrey Bell; Mark F Brady; Robert C Young; Janice Lage; Joan L Walker; Katherine Y Look; G Scott Rose; Nick M Spirtos
Journal:  Gynecol Oncol       Date:  2006-07-24       Impact factor: 5.482

7.  Lymph node metastasis in patients with epithelial ovarian cancer macroscopically confined to the ovary: review of a single-institution experience.

Authors:  Volkan Ulker; Oguzhan Kuru; Ceyhun Numanoglu; Ozgur Akbayır; Ibrahim Polat; Mehmet Uhri
Journal:  Arch Gynecol Obstet       Date:  2013-11-09       Impact factor: 2.344

8.  International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.

Authors:  J Baptist Trimbos; Mahesh Parmar; Ignace Vergote; David Guthrie; Giorgio Bolis; Nicoletta Colombo; Jan B Vermorken; Valter Torri; Constantino Mangioni; Sergio Pecorelli; Andrea Lissoni; Ann Marie Swart
Journal:  J Natl Cancer Inst       Date:  2003-01-15       Impact factor: 13.506

9.  Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.

Authors:  John K Chan; Deanna Teoh; Jessica M Hu; Jacob Y Shin; Kathryn Osann; Daniel S Kapp
Journal:  Gynecol Oncol       Date:  2008-04-18       Impact factor: 5.482

10.  International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer.

Authors:  Nicoletta Colombo; David Guthrie; Stefania Chiari; Mahesh Parmar; Wendi Qian; Ann Marie Swart; Valter Torri; Christopher Williams; Andrea Lissoni; Cristina Bonazzi
Journal:  J Natl Cancer Inst       Date:  2003-01-15       Impact factor: 13.506

View more
  4 in total

1.  Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinoma.

Authors:  Yuji Takei; Suzuyo Takahashi; Shizuo Machida; Akiyo Taneichi; Takahiro Yoshiba; Yoshifumi Takahashi; Chikako Yoshida; Yasushi Saga; Shigeki Matsubara; Hiroyuki Fujiwara
Journal:  Int J Clin Oncol       Date:  2018-04-20       Impact factor: 3.402

2.  Therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma.

Authors:  Hiroyuki Yamazaki; Yukiharu Todo; Chisa Shimada; Sho Takeshita; Shinichiro Minobe; Kazuhira Okamoto; Katsushige Yamashiro; Hidenori Kato
Journal:  J Gynecol Oncol       Date:  2017-12-11       Impact factor: 4.401

3.  Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.

Authors:  Chenchen Zhu; Jing Zhu; Lili Qian; Hanyuan Liu; Zhen Shen; Dabao Wu; Weidong Zhao; Weihua Xiao; Ying Zhou
Journal:  BMC Cancer       Date:  2021-03-25       Impact factor: 4.430

4.  Omission of adjuvant therapy in stage I clear cell ovarian cancer: Review of the BC Cancer experience.

Authors:  Shiru L Liu; Anna V Tinker
Journal:  Gynecol Oncol Rep       Date:  2019-12-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.